In this respect, combination of rituximab with CD47 antibody targeting is being clinically evaluated for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NCT02953509). Here, CD47 is linked to B-cell non-Hodgkin lymphoma.